RET and non-small cell lung carcinoma: Studies on some multi-targeted TKIs exhibiting activity on RET were conducted in NSCLC patients with RET fusion-positive, including Cabozantinib,24 Vandetanib,25,33 Lenvatinib,26 Ponatinib,34 Sunitinib,35 and Sorafenib.36 Among those TKIs, low to moderate antitumor activity was observed, but none received FDA approval for this indication.